AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 SEP 19 - (NewsRx.com & NewsRx.net) -- Cel-Sci Corp. (CVM), a developer of cancer immuno-therapy treatments, announced that the American Stock Exchange (AMEX) has accepted the company's plan to bring itself into compliance with the AMEX continued listing standards.
The AMEX has previously discussed with the company that it was below certain of AMEX's continued listing guidelines.
The company was afforded an opportunity to submit a plan of compliance and Cel-Sci presented its plan to the AMEX. The AMEX has accepted the plan of compliance and granted Cel-Sci an extension of time to gain compliance with the continued listing standards.
Cel-Sci has been notified by the Exchange that, subject to periodic reviews and ...